Literature DB >> 15175147

Dry eye: diagnosis and current treatment strategies.

Paul D O'Brien1, Louis M T Collum.   

Abstract

One in four patients attending ophthalmic clinics report symptoms of dry eye, making it one of the most common complaints seen by ophthalmologists. Aqueous-layer deficiency is the most common form of dry eye and is frequently caused by decreased secretion of tears by the lacrimal glands. Evaporative dry eye is often secondary to meibomian gland disease and results in a defective lipid layer. Tear replacement or preservation using artificial tears and/or punctal occlusion are the mainstay of treatment. Newer forms of therapy were designed to modify the underlying disease process. These include the use of topical cyclosporin A, autologous serum, and sodium hyaluronate drops, which suppress underlying inflammation, provide growth factors, and prevent the onset of squamous metaplasia in ocular surface epithelium. Hormonal therapy might have a role in the future of dry eye therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175147     DOI: 10.1007/s11882-004-0077-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  35 in total

1.  Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.

Authors:  Benjamin R Yerxa; Mohan Mundasad; Robin N Sylvester; JoAnn C Garden; Mark Cooper; Donald J Kellerman
Journal:  Adv Exp Med Biol       Date:  2002       Impact factor: 2.622

2.  Aqueous tear production in patients with neurotrophic keratitis.

Authors:  T J Heigle; S C Pflugfelder
Journal:  Cornea       Date:  1996-03       Impact factor: 2.651

3.  Diagnostic implications of tear protein profiles.

Authors:  I A Mackie; D V Seal
Journal:  Br J Ophthalmol       Date:  1984-05       Impact factor: 4.638

4.  Treatment of dry eye by autologous serum application in Sjögren's syndrome.

Authors:  K Tsubota; E Goto; H Fujita; M Ono; H Inoue; I Saito; S Shimmura
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

5.  Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion.

Authors:  K Turner; S C Pflugfelder; Z Ji; W J Feuer; M Stern; B L Reis
Journal:  Cornea       Date:  2000-07       Impact factor: 2.651

6.  P2Y(2) receptor stimulation increases tear fluid secretion in rabbits.

Authors:  T Murakami; T Fujihara; M Nakamura; K Nakata
Journal:  Curr Eye Res       Date:  2000-10       Impact factor: 2.424

7.  Iatrogenic complications related to the use of Herrick Lacrimal Plugs.

Authors:  W L White; G B Bartley; M J Hawes; J V Linberg; D B Leventer
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

8.  Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine.

Authors:  Kathleen S Kunert; Ann S Tisdale; Ilene K Gipson
Journal:  Arch Ophthalmol       Date:  2002-03

9.  Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface?

Authors:  Jennifer M Cermak; Kathleen L Krenzer; Rose M Sullivan; M Reza Dana; David A Sullivan
Journal:  Cornea       Date:  2003-08       Impact factor: 2.651

10.  Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study.

Authors:  N Tsifetaki; G Kitsos; C A Paschides; Y Alamanos; V Eftaxias; P V Voulgari; K Psilas; A A Drosos
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

View more
  48 in total

1.  Choosing Core Outcomes for Use in Clinical Trials in Ophthalmology: Perspectives from Three Ophthalmology Outcomes Working Groups.

Authors:  Ian J Saldanha; Jimmy T Le; Sharon D Solomon; Michael X Repka; Esen K Akpek; Tianjing Li
Journal:  Ophthalmology       Date:  2019-01       Impact factor: 12.079

2.  Eye reflux: an ocular extraesophageal manifestation of gastric reflux.

Authors:  Danilo Mazzacane; Valerio Damiani; Michela Silvestri; Giorgio Ciprandi; Pierfranco Marino
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

3.  Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease.

Authors:  Kyung-Sun Na; Man Soo Kim
Journal:  J Ocul Pharmacol Ther       Date:  2012-06-25       Impact factor: 2.671

Review 4.  The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review.

Authors:  Divi Cornec; Alain Saraux; Sandrine Jousse-Joulin; Jacques-Olivier Pers; Sylvie Boisramé-Gastrin; Yves Renaudineau; Yves Gauvin; Anne-Marie Roguedas-Contios; Steeve Genestet; Myriam Chastaing; Béatrice Cochener; Valérie Devauchelle-Pensec
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

5.  Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment in Dry Eye.

Authors:  Francisco Amparo; Debra A Schaumberg; Reza Dana
Journal:  Ophthalmology       Date:  2015-04-08       Impact factor: 12.079

6.  Effect of topically applied epithelial sodium channel inhibitors on tear production in normal mice and in mice with induced aqueous tear deficiency.

Authors:  William R Thelin; M Ross Johnson; Andrew J Hirsh; Claire L Kublin; Driss Zoukhri
Journal:  J Ocul Pharmacol Ther       Date:  2012-03-28       Impact factor: 2.671

7.  Corneal sensitivity following lacrimal gland excision in the rat.

Authors:  Ian D Meng; Stephen T Barton; Neal E Mecum; Masayuki Kurose
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

8.  Research Questions and Outcomes Prioritized by Patients With Dry Eye.

Authors:  Ian J Saldanha; Rebecca Petris; Genie Han; Kay Dickersin; Esen K Akpek
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

9.  Etiology, prevalence, and treatment of dry eye disease.

Authors:  Johnny L Gayton
Journal:  Clin Ophthalmol       Date:  2009-07-14

10.  A cerium oxide loaded glycol chitosan nano-system for the treatment of dry eye disease.

Authors:  Fan Yu; Min Zheng; Alice Yang Zhang; Zongchao Han
Journal:  J Control Release       Date:  2019-10-24       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.